ROR1 and neoplasm: A monoclonal antibody (cirmtuzumab) was developed by binding to ROR1 on tumor cells and inhibiting Wnt5a signaling, which is a pathway that is important for blocking tumor‐cell proliferation, migration, and survival.180 The antibody has been used in a phase I clinical trial for chronic lymphocytic leukemia.175, 178, 179, 181, 182